Zetagen Therapeutics, Inc. Awarded $225,000 USD Grant from NIAMS for Phase I Study of Novel Osteoinductive Lumbar Fusion Implant for Small Molecule-Based

• Award comes from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH)
• U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
• Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Event) (SRE’s) and osteologic interventions

September 11, 2019, (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of $225,000 USD from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). The grant will be used for a Phase I validation study of a novel, surgical implant for use with the Company’s small-molecule ZetaFuse™. The implant is designed to repair damaged bone through stem cell activation.

“We are extremely pleased to be recognized by the NIAMS, allowing us to enter our next phase of research,” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. “This study further builds on our earlier validation studies, allowing us to now focus on how to successfully repair damaged bone by activating the body’s own stem cells – something which can potentially be applied beyond osteolytic cancers to other orthopedic interventions.”

The NIAMS grant is part of the Small Business Innovation Research Program (SBIR), a three phase award system created by the Federal Government for small businesses to engage in research and development that has the potential for commercialization and public benefit. Zetagen exclusively-licensed its platform technology from the State University of New York in 2016.